SPONSOR
UNICANCER
Total Trials
8
Recruiting
8
Phases
Phase 3, Phase 2
Conditions studied: High Risk Prostate CarcinomaProstate CancerBreast Cancer Nos Metastatic RecurrentEarly Lung CancerProstate Cancer MetastaticLung Cancer MetastaticRenal Cell CarcinomaHead and Neck CancerTriple Negative Breast CancerMerkel Cell Carcinoma
UNICANCER is a clinical research sponsor with 8 registered studies on ClinicalTrials.gov, of which 8 are actively recruiting participants. Research covers conditions including High Risk Prostate Carcinoma, Prostate Cancer, Breast Cancer Nos Metastatic Recurrent, Early Lung Cancer.
The trial portfolio spans Phase 3, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — UNICANCER
How many clinical trials has UNICANCER sponsored?
ClinicalMetric currently tracks 8 clinical trials sponsored by UNICANCER, of which 8 are actively recruiting participants. These trials cover conditions including High Risk Prostate Carcinoma, Prostate Cancer, Breast Cancer Nos Metastatic Recurrent. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does UNICANCER research focus on?
UNICANCER clinical trials span High Risk Prostate Carcinoma, Prostate Cancer, Breast Cancer Nos Metastatic Recurrent, Early Lung Cancer, Prostate Cancer Metastatic, and additional conditions. The research pipeline includes Phase 3, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a UNICANCER clinical trial?
To participate in a UNICANCER trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all UNICANCER trials with current recruitment status updated daily.
Clinical Trials by UNICANCER
NCT06625970 Phase 3
Recruiting
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
High Risk Prostate Carcinoma
NCT01993498
Recruiting
Chronic Toxicities Related to Treatment in Patients With Localized Cancer
Breast Cancer Nos Metastatic Recurrent
NCT04916613 Phase 3
Recruiting
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
Prostate Cancer Metastatic
NCT06496581 Phase 3
Recruiting
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
Prostate Cancer Metastatic
NCT05078047 Phase 3
Recruiting
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Lung Cancer Metastatic
NCT07259226 Phase 2
Recruiting
Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers
Advanced Breast Cancer
NCT06245356 Phase 2
Recruiting
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
Metastatic Colorectal Cancer
NCT06276465 Phase 3
Recruiting
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
Prostatic Cancer, Castration-Resistant
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology